**Deubiquitinase MYSM1 in the Hematopoietic System and beyond: A Current Review**

**Amanda Fiore 1,2, Yue Liang 1,2, Yun Hsiao Lin 1,2, Jacky Tung 1,2, HanChen Wang 1,2,3, David Langlais 2,3,4 and Anastasia Nijnik 1,2,\***


Received: 4 April 2020; Accepted: 20 April 2020; Published: 24 April 2020

**Abstract:** MYSM1 has emerged as an important regulator of hematopoietic stem cell function, blood cell production, immune response, and other aspects of mammalian physiology. It is a metalloprotease family protein with deubiquitinase catalytic activity, as well as SANT and SWIRM domains. MYSM1 normally localizes to the nucleus, where it can interact with chromatin and regulate gene expression, through deubiquitination of histone H2A and non-catalytic contacts with other transcriptional regulators. A cytosolic form of MYSM1 protein was also recently described and demonstrated to regulate signal transduction pathways of innate immunity, by promoting the deubiquitination of TRAF3, TRAF6, and RIP2. In this work we review the current knowledge on the molecular mechanisms of action of MYSM1 protein in transcriptional regulation, signal transduction, and potentially other cellular processes. The functions of MYSM1 in different cell types and aspects of mammalian physiology are also reviewed, highlighting the key checkpoints in hematopoiesis, immunity, and beyond regulated by MYSM1. Importantly, mutations in MYSM1 in human were recently linked to a rare hereditary disorder characterized by leukopenia, anemia, and other hematopoietic and developmental abnormalities. Our growing knowledge of MYSM1 functions and mechanisms of actions sheds important insights into its role in mammalian physiology and the etiology of the MYSM1-deficiency disorder in human.

**Keywords:** deubiquitinase; hematopoiesis; hematopoietic stem cells; immune response; regulation of gene expression
